

# Richard T Silver

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6474497/publications.pdf>

Version: 2024-02-01

152  
papers

10,840  
citations

87843

38  
h-index

30894

102  
g-index

156  
all docs

156  
docs citations

156  
times ranked

7103  
citing authors

#	ARTICLE	IF	CITATIONS
1	European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013. <i>Blood</i> , 2013, 122, 872-884.	0.6	1,743
2	Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet. <i>Journal of Clinical Oncology</i> , 2009, 27, 6041-6051.	0.8	1,188
3	Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study. <i>Blood</i> , 2002, 99, 1928-1937.	0.6	943
4	Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders. <i>Blood</i> , 2005, 106, 2162-2168.	0.6	798
5	Philadelphia-Negative Classical Myeloproliferative Neoplasms: Critical Concepts and Management Recommendations From European LeukemiaNet. <i>Journal of Clinical Oncology</i> , 2011, 29, 761-770.	0.8	724
6	Arabinosyl Cytosine: A Useful Agent in the Treatment of Acute Leukemia in Adults. <i>Blood</i> , 1968, 32, 507-523.	0.6	521
7	Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. <i>Leukemia</i> , 2018, 32, 1057-1069.	3.3	415
8	International Working Group (IWG) consensus criteria for treatment response in myelofibrosis with myeloid metaplasia, for the IWG for Myelofibrosis Research and Treatment (IWG-MRT). <i>Blood</i> , 2006, 108, 1497-1503.	0.6	317
9	Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. <i>Journal of Hematology and Oncology</i> , 2017, 10, 55.	6.9	302
10	Efficacy, safety, and survival with ruxolitinib in patients with myelofibrosis: results of a median 3-year follow-up of COMFORT-I. <i>Haematologica</i> , 2015, 100, 479-488.	1.7	246
11	Janus kinase-2 inhibitor fedratinib in patients with myelofibrosis previously treated with ruxolitinib (JAKARTA-2): a single-arm, open-label, non-randomised, phase 2, multicentre study. <i>Lancet Haematology</i> , 2017, 4, e317-e324.	2.2	243
12	Highly Sensitive Fluorescence In Situ Hybridization Method to Detect Double BCR/ABL Fusion and Monitor Response to Therapy in Chronic Myeloid Leukemia. <i>Blood</i> , 1998, 91, 3357-3365.	0.6	180
13	The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal. <i>Blood</i> , 2008, 112, 231-239.	0.6	158
14	Long-term effects of the treatment of polycythemia vera with recombinant interferon- $\alpha$ . <i>Cancer</i> , 2006, 107, 451-458.	2.0	143
15	Characteristics of the Terminal Phase of Chronic Granulocytic Leukemia. <i>Blood</i> , 1968, 32, 445-459.	0.6	141
16	Hodgkin disease survivors at increased risk for problems in psychosocial adaptation. <i>Cancer</i> , 1992, 70, 2214-2224.	2.0	139
17	Pegylated interferon alfa-2a for polycythemia vera or essential thrombocythemia resistant or intolerant to hydroxyurea. <i>Blood</i> , 2019, 134, 1498-1509.	0.6	123
18	Recombinant interferon- $\alpha$ may retard progression of early primary myelofibrosis: a preliminary report. <i>Blood</i> , 2011, 117, 6669-6672.	0.6	122

#	ARTICLE	IF	CITATIONS
19	Minimal molecular response in polycythemia vera patients treated with imatinib or interferon alpha. <i>Blood</i> , 2006, 107, 3339-3341.	0.6	113
20	Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis. <i>Blood</i> , 2013, 122, 1881-1886.	0.6	99
21	Interferon and the treatment of polycythemia vera, essential thrombocythemia and myelofibrosis. <i>Expert Review of Hematology</i> , 2013, 6, 49-58.	1.0	96
22	Fedratinib in patients with myelofibrosis previously treated with ruxolitinib: An updated analysis of the JAKAR2 study using stringent criteria for ruxolitinib failure. <i>American Journal of Hematology</i> , 2020, 95, 594-603.	2.0	96
23	A Special Fluorescent In Situ Hybridization Technique to Study Peripheral Blood and Assess the Effectiveness of Interferon Therapy in Chronic Myeloid Leukemia. <i>Blood</i> , 1998, 92, 2315-2321.	0.6	71
24	Clinical trial of VP 16 (NSC 141540) I.V. Twice weekly in advanced neoplastic disease a study by the cancer and leukemia group B. <i>Cancer</i> , 1980, 45, 232-235.	2.0	70
25	Management of chronic myeloid leukemia in blast crisis. <i>Annals of Hematology</i> , 2015, 94, 159-165.	0.8	61
26	Four Years of Follow-Up of 1027 Patients with Late Chronic Phase (L-CP), Accelerated Phase (AP), or Blast Crisis (BC) Chronic Myeloid Leukemia (CML) Treated with Imatinib in Three Large Phase II Trials. <i>Blood</i> , 2004, 104, 23-23.	0.6	61
27	Amplification Refractory Mutation System, a Highly Sensitive and Simple Polymerase Chain Reaction Assay, for the Detection of JAK2 V617F Mutation in Chronic Myeloproliferative Disorders. <i>Journal of Molecular Diagnostics</i> , 2007, 9, 272-276.	1.2	60
28	Management of CML-blast crisis. <i>Best Practice and Research in Clinical Haematology</i> , 2016, 29, 295-307.	0.7	60
29	Risk Factors for Severe Neuropsychiatric Toxicity in Patients Receiving Interferon Alfa-2b and Low-Dose Cytarabine for Chronic Myelogenous Leukemia: Analysis of Cancer and Leukemia Group B 9013. <i>Journal of Clinical Oncology</i> , 2000, 18, 1301-1308.	0.8	58
30	Interferon- 2b: A New Treatment for Polycythemia Vera. <i>Annals of Internal Medicine</i> , 1993, 119, 1091.	2.0	57
31	JAK2V617F allele burden in polycythemia vera correlates with grade of myelofibrosis, but is not substantially affected by therapy. <i>Leukemia Research</i> , 2011, 35, 177-182.	0.4	56
32	Interferon-alpha for treating polycythemia vera yields improved myelofibrosis-free and overall survival. <i>Leukemia</i> , 2021, 35, 2592-2601.	3.3	52
33	Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia. <i>JAMA Oncology</i> , 2021, 7, 42.	3.4	51
34	Recombinant interferon- $\alpha$ in myelofibrosis reduces bone marrow fibrosis, improves its morphology and is associated with clinical response. <i>Modern Pathology</i> , 2015, 28, 1315-1323.	2.9	49
35	The effect of initial molecular profile on response to recombinant interferon- $\alpha$ (rIFN $\alpha$ ) treatment in early myelofibrosis. <i>Cancer</i> , 2017, 123, 2680-2687.	2.0	48
36	Appropriate management of polycythaemia vera with cytoreductive drug therapy: European LeukemiaNet 2021 recommendations. <i>Lancet Haematology</i> , 2022, 9, e301-e311.	2.2	46

#	ARTICLE	IF	CITATIONS
37	A randomized phase 3 trial of interferon- $\beta$ vs hydroxyurea in polycythemia vera and essential thrombocythemia. <i>Blood</i> , 2022, 139, 2931-2941.	0.6	45
38	PRM-151 in Myelofibrosis: Efficacy and Safety in an Open Label Extension Study. <i>Blood</i> , 2018, 132, 686-686.	0.6	44
39	Strategies that delay or prevent the timely availability of affordable generic drugs in the United States. <i>Blood</i> , 2016, 127, 1398-1402.	0.6	42
40	Results of the Myeloproliferative Neoplasms - Research Consortium (MPN-RC) 112 Randomized Trial of Pegylated Interferon Alfa-2a (PEG) Versus Hydroxyurea (HU) Therapy for the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET). <i>Blood</i> , 2018, 132, 577-577.	0.6	39
41	Use of Testosterone and Busulfan in the Treatment of Myelofibrosis with Myeloid Metaplasia. <i>Blood</i> , 1964, 23, 341-353.	0.6	33
42	JAK2V617F allele burden is reduced by busulfan therapy: a new observation using an old drug. <i>Haematologica</i> , 2013, 98, e135-e137.	1.7	33
43	European LeukemiaNet study on the reproducibility of bone marrow features in masked polycythemia vera and differentiation from essential thrombocythemia. <i>American Journal of Hematology</i> , 2017, 92, 1062-1067.	2.0	33
44	Interim Analysis of the Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia. <i>Blood</i> , 2016, 128, 479-479.	0.6	32
45	Decrease in JAK2V617F allele burden is not a prerequisite to clinical response in patients with polycythemia vera. <i>Haematologica</i> , 2012, 97, 538-542.	1.7	31
46	Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. <i>Haematologica</i> , 2018, 103, e392-e394.	1.7	31
47	Phase 2 Trial of PRM-151, an Anti-Fibrotic Agent, in Patients with Myelofibrosis: Stage 1 Results. <i>Blood</i> , 2014, 124, 713-713.	0.6	31
48	Ruxolitinib for Myelofibrosis—An Update of Its Clinical Effects. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, 638-645.	0.2	30
49	PRM-151 in Myelofibrosis: Durable Efficacy and Safety at 72 Weeks. <i>Blood</i> , 2015, 126, 56-56.	0.6	28
50	Correlation of three methods of measuring cytogenetic response in chronic myelocytic leukemia. <i>Cancer Genetics and Cytogenetics</i> , 2002, 137, 79-84.	1.0	22
51	The blast phase of chronic myeloid leukaemia. <i>Best Practice and Research in Clinical Haematology</i> , 2009, 22, 387-394.	0.7	22
52	Jumping translocations of the long arms of chromosome 1 in myeloid malignancies is associated with a high risk of transformation to acute myeloid leukaemia*. <i>British Journal of Haematology</i> , 2010, 151, 288-291.	1.2	21
53	Treatment of polycythemia vera with imatinib mesylate. <i>Leukemia Research</i> , 2012, 36, 156-162.	0.4	21
54	A Phase I Study of XL019, a Selective JAK2 Inhibitor, in Patients with Polycythemia Vera. <i>Blood</i> , 2008, 112, 2810-2810.	0.6	21

#	ARTICLE	IF	CITATIONS
55	Long-Term Outcomes Of Ruxolitinib Therapy In Patients With Myelofibrosis: 3-Year Update From COMFORT-I. <i>Blood</i> , 2013, 122, 396-396.	0.6	21
56	The Importance of Bone Marrow Biopsy in the Staging of Patients With Lymphosarcoma. <i>Blood</i> , 1973, 41, 913-920.	0.6	20
57	Interferon Alfa in the Treatment of Philadelphia-Negative Chronic Myeloproliferative Neoplasms. <i>Journal of Clinical Oncology</i> , 2011, 29, e564-e565.	0.8	20
58	Fedratinib Improves Myelofibrosis-related Symptoms and Health-related Quality of Life in Patients with Myelofibrosis Previously Treated with Ruxolitinib: Patient-reported Outcomes from the Phase II JAKARTA2 Trial. <i>HemaSphere</i> , 2021, 5, e562.	1.2	20
59	Allogeneic Transplantation for Patients With Advanced Myelofibrosis: Splenomegaly and High Serum LDH are Adverse Risk Factors for Successful Engraftment. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2016, 16, 297-303.	0.2	19
60	Long-Term Outcome of Ruxolitinib Treatment in Patients with Myelofibrosis: Durable Reductions in Spleen Volume, Improvements in Quality of Life, and Overall Survival Advantage in COMFORT-I. <i>Blood</i> , 2012, 120, 800-800.	0.6	19
61	Treatment of the Chronic Phase of Chronic Myeloid Leukemia with an Intermittent Schedule of Recombinant Interferon Alfa-2b and Cytarabine: Results from CALGB Study 9013. <i>Leukemia and Lymphoma</i> , 2003, 44, 39-48.	0.6	17
62	New Perspectives of Interferon-alpha2 and Inflammation in Treating Philadelphia-negative Chronic Myeloproliferative Neoplasms. <i>HemaSphere</i> , 2021, 5, e645.	1.2	17
63	Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients. <i>Cancer Medicine</i> , 2019, 8, 4089-4092.	1.3	16
64	Normal life expectancy for polycythemia vera (PV) patients is possible. <i>Leukemia</i> , 2022, 36, 569-572.	3.3	16
65	Design and rationale for the life after stopping tyrosine kinase inhibitors (LAST) study, a prospective, single-group longitudinal study in patients with chronic myeloid leukemia. <i>BMC Cancer</i> , 2018, 18, 359.	1.1	15
66	High dose methotrexate with citrovorum factor in adult resistant lymphoma. <i>Cancer</i> , 1977, 40, 2823-2828.	2.0	14
67	Chronic myeloid leukemia. <i>Hematology/Oncology Clinics of North America</i> , 2003, 17, 1159-1173.	0.9	14
68	Optimal therapy for polycythemia vera and essential thrombocythemia: Preferred use of interferon therapy based on phase 2 trials. <i>Hematology</i> , 2016, 21, 387-391.	0.7	14
69	Distinguishing essential thrombocythemia <i>JAK2</i>V617F from polycythemia vera: limitations of erythrocyte values. <i>Haematologica</i> , 2019, 104, 2200-2205.	1.7	14
70	Consistent Benefit of Ruxolitinib Over Placebo in Spleen Volume Reduction and Symptom Improvement Across Subgroups and Overall Survival Advantage: Results From COMFORT-I. <i>Blood</i> , 2011, 118, 278-278.	0.6	14
71	Interferon in polycythemia vera and related neoplasms. Can it become the treatment of choice without a randomized trial?. <i>Expert Review of Hematology</i> , 2015, 8, 439-445.	1.0	13
72	Phenotype variability of patients with post polycythemia vera and post essential thrombocythemia myelofibrosis is associated with the time to progression from polycythemia vera and essential thrombocythemia. <i>Leukemia Research</i> , 2018, 69, 100-102.	0.4	13

#	ARTICLE	IF	CITATIONS
73	Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. <i>Blood Cancer Journal</i> , 2018, 8, 89.	2.8	13
74	Efficacy and Safety Of Fedratinib (SAR302503/TG101348) In Patients With Intermediate- Or High-Risk Myelofibrosis (MF), Post-Polycythemia Vera (PV) MF, Or Post-Essential Thrombocythemia (ET) MF Previously Treated With Ruxolitinib: Interim Results From a Phase II Study (JAKARTA-2). <i>Blood</i> , 2013, 122, 661-661.	0.6	13
75	Uncommon or Delayed Adverse Events Associated With Imatinib Treatment for Chronic Myeloid Leukemia. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2010, 10, 331-335.	0.2	12
76	Incremental Utility of Right Ventricular Dysfunction in Patients With Myeloproliferative Neoplasm-Associated Pulmonary Hypertension. <i>Journal of the American Society of Echocardiography</i> , 2019, 32, 1574-1585.	1.2	12
77	Ruxolitinib Discontinuation In Patients With Myelofibrosis: An Analysis From Clinical Practice. <i>Blood</i> , 2013, 122, 2833-2833.	0.6	12
78	Treatment of Polycythemia Vera. <i>Seminars in Thrombosis and Hemostasis</i> , 2006, 32, 437-442.	1.5	11
79	Single agent bevacizumab for myelofibrosis: results of the Myeloproliferative Disorders Research Consortium Trial. <i>Haematologica</i> , 2013, 98, 1421-1423.	1.7	11
80	The hematocrit value in polycythemia vera: caveat utilitor. <i>Leukemia and Lymphoma</i> , 2015, 56, 1540-1541.	0.6	11
81	A comparative study of dibromomannitol and busulfan in the treatment of chronic myeloid leukemia. A study of cancer and leukemia group B. <i>Cancer</i> , 1987, 60, 1442-1448.	2.0	10
82	Combination trial of subcutaneous recombinant $\alpha$ 2b interferon and oral cyclophosphamide in follicular low-grade non-Hodgkin's lymphoma. <i>Medical and Pediatric Oncology</i> , 1994, 22, 228-235.	1.0	10
83	Patient-Reported Functional Outcomes in Patients With Chronic Myeloid Leukemia After Stopping Tyrosine Kinase Inhibitors. <i>Journal of the National Cancer Institute</i> , 2022, 114, 160-164.	3.0	9
84	Post-Polycythemia and Post-Thrombocythemia Myelofibrosis Have Distinctive Clinical Phenotypes: An International Multicenter Study on 718 Patients. <i>Blood</i> , 2014, 124, 1824-1824.	0.6	9
85	Fedratinib (FEDR) in myelofibrosis (MF) patients previously treated with ruxolitinib (RUX): A reanalysis of the JAKARTA-2 study.. <i>Journal of Clinical Oncology</i> , 2019, 37, 7057-7057.	0.8	9
86	Evaluation of bone marrow morphology is essential for assessing disease status in recombinant interferon $\alpha$ -treated polycythemia vera patients. <i>Haematologica</i> , 2017, 102, e97-e99.	1.7	8
87	Impact of bone marrow fibrosis grade in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: A study of the MYSEC group. <i>American Journal of Hematology</i> , 2020, 95, E1-E3.	2.0	8
88	Tumor Necrosis Factor-Alpha (TNF) Expression Is Elevated in Myelo-Proliferative Neoplasms (MPN) and Modulated by Inhibition of JAK2 V617F.. <i>Blood</i> , 2009, 114, 2917-2917.	0.6	8
89	HAC-cytoxan (cyclophosphamide) chemotherapy for ovarian carcinoma. <i>Alternating Chemotherapy With Intensification</i> . <i>Cancer</i> , 1985, 55, 2342-2347.	2.0	7
90	Prognostic significance of additional cytogenetic abnormalities in newly diagnosed patients with Philadelphia chromosome-positive chronic myelogenous leukemia treated with interferon- $\alpha$ : A Cancer and Leukemia Group B study. <i>International Journal of Oncology</i> , 2004, 25, 143.	1.4	7

#	ARTICLE	IF	CITATIONS
91	Response to pegylated interferon in a COVID-19 positive elderly woman with primary myelofibrosis treated with ruxolitinib. <i>Clinical Case Reports (discontinued)</i> , 2021, 9, 2228-2235.	0.2	7
92	Preliminary safety and efficacy of ruxolitinib in patients (pts) with primary and secondary myelofibrosis (MF) with platelet counts (PC) of $50 \times 10^9 / L$ . <i>Journal of Clinical Oncology</i> , 2012, 30, 6630-6630.	0.8	7
93	Unusual translocations involving chromosomes 12;22 and 9;12 in a case of chronic myelogenous leukemia. <i>Cancer Genetics and Cytogenetics</i> , 1985, 14, 61-65.	1.0	6
94	Recombinant Gamma-Interferon Has Activity in Chronic Myeloid Leukemia. <i>American Journal of Clinical Oncology: Cancer Clinical Trials</i> , 1990, 13, 49-54.	0.6	6
95	Evaluation of serum erythropoietin values as defined by 2016 World Health Organization criteria for the diagnosis of polycythemia vera. <i>Leukemia and Lymphoma</i> , 2017, 58, 2768-2769.	0.6	6
96	What Is the Most Cost-Effective Strategy for Treating Newly Diagnosed Chronic Phase Chronic Myeloid Leukemia (CML) after Imatinib Loses Patent Exclusivity?. <i>Blood</i> , 2014, 124, 738-738.	0.6	6
97	Platelet Amino Acid Levels in Essential Thrombocytosis. <i>Blood</i> , 1966, 27, 715-721.	0.6	5
98	Treatment of advanced ovarian carcinoma with hexamethylmelamine, doxorubicin, and cis-platinum (HAC): Results in both untreated and previously treated patients. <i>Medical and Pediatric Oncology</i> , 1984, 12, 17-24.	1.0	5
99	Imatinib Mesylate (GLEEVEC®) Is Effective in the Treatment of Polycythemia Vera: A Multi-Institutional Clinical Trial. <i>Blood</i> , 2004, 104, 656-656.	0.6	5
100	Associations Between Improvements in Myelofibrosis (MF) Symptoms and Quality of Life Measures with Splenomegaly Reduction in COMFORT-I: A Randomized, Double-Blind, Phase III Trial of the JAK1 and JAK2 Inhibitor Ruxolitinib Versus Placebo in Patients with MF. <i>Blood</i> , 2011, 118, 3842-3842.	0.6	5
101	Recombinant Interferon Alpha (rIFN) May Retard Progression Of Early Myelofibrosis By Reducing Splenomegaly and By Decreasing Marrow Fibrosis. <i>Blood</i> , 2013, 122, 4053-4053.	0.6	5
102	Impact on MPN Symptoms and Quality of Life of Front Line Pegylated Interferon Alpha-2a Vs. Hydroxyurea in High Risk Polycythemia Vera and Essential Thrombocythemia: Interim Analysis Results of Myeloproliferative Disorders Research Consortium (MPD-RC) 112 Global Phase III Trial. <i>Blood</i> , 2016, 128, 4271-4271.	0.6	5
103	Treatment of polycythemia vera with recombinant interferon alpha (rIFNalpha) or imatinib mesylate. <i>Psychophysiology</i> , 2005, 4, 235-7.	1.1	5
104	Excess mortality in younger patients with myeloproliferative neoplasms. <i>Leukemia and Lymphoma</i> , 2023, 64, 725-729.	0.6	5
105	Spatial relationship of chromosomes 9 and 22 at metaphase in patients with chronic myelogenous leukemia (CML). <i>International Journal of Cancer</i> , 1988, 41, 829-831.	2.3	4
106	The treatment of essential thrombocytosis revisited. <i>Blood</i> , 2011, 118, 1179-1180.	0.6	4
107	Interferon in Polycythemia Vera (PV) Yields Improved Myelofibrosis-Free and Overall Survival. <i>Blood</i> , 2020, 136, 31-32.	0.6	4
108	A New International Multicenter-Based Model to Predict Survival in Myelofibrosis Secondary to Polycythemia and Thrombocythemia: The Mysec Prognostic Model (MYSEC-PM). <i>Blood</i> , 2014, 124, 1826-1826.	0.6	4

#	ARTICLE	IF	CITATIONS
109	Patient- and physician-reported pain after tyrosine kinase inhibitor discontinuation among patients with chronic myeloid leukemia. <i>Haematologica</i> , 2022, 107, 2641-2649.	1.7	4
110	Hematopoietic fitness of <i>JAK2V617F</i> myeloproliferative neoplasms is linked to clinical outcome. <i>Blood Advances</i> , 2022, 6, 5477-5481.	2.5	4
111	The use of low-dose prednisone and melphalan in the treatment of poor-risk patients with multiple myeloma. <i>Medical and Pediatric Oncology</i> , 1975, 1, 207-216.	1.0	3
112	Administration of a complex chemotherapy regimen: Inpatient versus outpatient treatment. <i>Medical and Pediatric Oncology</i> , 1983, 11, 333-335.	1.0	3
113	Are All Interferons the Same for Therapy in Polycythemia Vera?. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2013, 13, S305-S306.	0.2	3
114	Arterial Thrombotic Complications Are Uncommon in Patients without Cardiovascular Risk Factors and Occur at Equivalent Rates in Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib and Nilotinib. <i>Blood</i> , 2014, 124, 1811-1811.	0.6	3
115	The Effect of Initial Molecular Profile on Response to Recombinant Interferon Alpha (rIFN $\alpha$ ) Treatment in Early Myelofibrosis. <i>Blood</i> , 2016, 128, 944-944.	0.6	3
116	Adverse events (AEs) and the return of myelofibrosis (MF)-related symptoms after interruption or discontinuation of ruxolitinib (RUX) therapy. <i>Journal of Clinical Oncology</i> , 2012, 30, 6624-6624.	0.8	3
117	Patient-Reported Outcome Results from the U.S. Life after Stopping TKIs (LAST) Study in Patients with Chronic Myeloid Leukemia. <i>Blood</i> , 2019, 134, 705-705.	0.6	3
118	Combination therapy with interferon and ruxolitinib for polycythemia vera and myelofibrosis: are two drugs better than one?. <i>Haematologica</i> , 2020, 105, 2190-2191.	1.7	3
119	Combination chemotherapy for non-Hodgkin lymphomas: A ten year follow-up study. <i>Medical and Pediatric Oncology</i> , 1979, 6, 23-38.	1.0	2
120	Update on the treatment of polycythemia vera with recombinant interferon alfa or imatinib mesylate. <i>Current Hematologic Malignancy Reports</i> , 2007, 2, 43-46.	1.2	2
121	Life, genes, and death in Philadelphia <sup>+</sup> MPNs. <i>Blood</i> , 2014, 124, 2471-2472.	0.6	2
122	Fedratinib Induces Spleen Responses in Patients with Myeloproliferative Neoplasm-Associated Intermediate- or High-Risk Myelofibrosis (MF) Previously Exposed to Ruxolitinib (RUX), Regardless of Reason for Discontinuing RUX. <i>Blood</i> , 2019, 134, 4165-4165.	0.6	2
123	JAK2 V617F Mutational Load in Patients with Polycythemia Vera (PV) Measured by Peripheral Blood DNA Is Associated with Disease Severity. <i>Blood</i> , 2007, 110, 2530-2530.	0.6	2
124	The JAK2 46/1 Haplotype Predisposes to Myeloproliferative Neoplasms Characterized by Diverse Mutations. <i>Blood</i> , 2009, 114, 433-433.	0.6	2
125	Prospective Evaluation of the World Health Organization Criteria for the Diagnosis of Polycythemia Vera. <i>Blood</i> , 2011, 118, 3837-3837.	0.6	2
126	Recombinant Interferon Alpha (rIFN $\alpha$ ) May Retard Progression of Early Primary Myelofibrosis (PM) by Reducing Splenomegaly and by Changing Marrow Morphology. <i>Blood</i> , 2008, 112, 1758-1758.	0.6	2



#	ARTICLE	IF	CITATIONS
127	Myelofibrosis: best practices, controversies and 2019 update. Expert Review of Hematology, 2020, 13, 71-84.	1.0	1
128	Clinical Burden and Progression of Myelofibrosis in a Controlled Study Population of Placebo-Treated Patients (COMFORT-I). Blood, 2011, 118, 5146-5146.	0.6	1
129	Phase 2 trial of PRM-151, an antifibrotic agent, in patients with myelofibrosis: Stage 1 results.. Journal of Clinical Oncology, 2014, 32, 7114-7114.	0.8	1
130	Long-term outcomes of ruxolitinib (RUX) therapy in patients (pts) with myelofibrosis (MF): 5-year update from COMFORT-I.. Journal of Clinical Oncology, 2016, 34, 7012-7012.	0.8	1
131	Effect of ADP and ATP Receptor Antagonism on Erythrocytosis-Induced Platelet Aggregate Formation under Dynamic Flow Conditions.. Blood, 2004, 104, 3903-3903.	0.6	1
132	Chronic Myeloid Leukemia (CML): A Model Disease for Utilizing Evidence Based Guidelines in a Decade of Progress.. Blood, 2006, 108, 3313-3313.	0.6	1
133	Allogeneic Stem Cell Transplantation for Patients with Chronic Myeloid Leukemia After Prior Treatment with Nilotinib or Dasatinib. Blood, 2010, 116, 2348-2348.	0.6	1
134	Health-Related Quality of Life (HRQoL) with Fedratinib, a Selective, Oral Inhibitor of Janus Kinase 2 (JAK2), in the Phase II JAKARTA2 Study in Patients with Intermediate- or High-Risk Myelofibrosis Previously Treated with Ruxolitinib. Blood, 2019, 134, 2207-2207.	0.6	1
135	Hematopoietic Stem and Progenitor Cell Fitness As a Novel Prognostic and Monitoring Biomarker for <i>JAK2 V617F</i> Myeloproliferative Neoplasms (MPNs). Blood, 2021, 138, 627-627.	0.6	1
136	Normal Life Expectancy for Polycythemia Vera Patients Is Possible. Blood, 2021, 138, 2575-2575.	0.6	1
137	The ABCs of myelofibrosis. Blood, 2005, 106, 2598-2599.	0.6	0
138	Predictive Value of In Vitro Mutation Data to Guide Second-Generation Tyrosine Kinase Inhibitor Selection: Ready for Prime Time?. Oncologist, 2011, 16, 554-558.	1.9	0
139	CML End Phase and Blast Crisis: Implications and Management. Hematologic Malignancies, 2021, , 179-196.	0.2	0
140	Pretreatment Cytogenetic Abnormalities in Polycythemia Vera (PV) Determines the Effectiveness of Imatinib : Studies from a Multi-Institutional Trial.. Blood, 2004, 104, 2431-2431.	0.6	0
141	No Significant Molecular Response in Polycythemia Vera Patients Treated with Imatinib or Interferon alpha.. Blood, 2005, 106, 373-373.	0.6	0
142	Correlation of Clinical and Molecular Response to Imatinib in Polycythemia Vera (PV) Patients with Bone Marrow Morphologic and Immunophenotypic Changes.. Blood, 2006, 108, 4914-4914.	0.6	0
143	JAK2 Mutations Are Present in All Cases of Polycythemia Vera.. Blood, 2007, 110, 4669-4669.	0.6	0
144	Development of V617F JAK2 Associated Myeloproliferative Neoplasms Is a Non-Random Event That Is Strongly Dependent on JAK2 Haplotype. Blood, 2008, 112, 173-173.	0.6	0

#	ARTICLE	IF	CITATIONS
145	A Novel in Vitro Model of Focal Fibrosis in Bone Marrow Stromal Co-Culture of CD34+ Cells From Patients with Idiopathic Myelofibrosis.. Blood, 2009, 114, 2896-2896.	0.6	0
146	Jumping Translocations of the Long Arms of Chromosome 1 (1qJ) in Myeloproliferative Neoplasms (MPNs) and Myelodysplastic Syndromes (MDS) Are Associated with High Risk of Transformation to Acute Myelogenous Leukemia (AML).. Blood, 2009, 114, 1567-1567.	0.6	0
147	In Vivo Imaging of Cerebral Circulation In Mouse Models of Polycythemia Vera. Blood, 2010, 116, 4091-4091.	0.6	0
148	Monocytes Modulate Megakaryocyte-Mediated Fibrosis of Bone Marrow Stromal Cells in Vitro. Blood, 2012, 120, 1759-1759.	0.6	0
149	Busulfan Induces Hematologic and Molecular Responses in Polycythemia Vera (PV) Refractory to Multiple Drugs. Blood, 2012, 120, 5068-5068.	0.6	0
150	Evaluation of Bone Marrow Morphology in Addition to JAK2 Allele Burden Is Essential for Assessing Disease Status in Recombinant Interferon Alpha-Treated Polycythemia Vera Patients. Blood, 2016, 128, 5471-5471.	0.6	0
151	Symptom Burden and Quality of Life in High-Risk Essential Thrombocythemia and Polycythemia Vera Patients Receiving Hydroxyurea or Pegylated Interferon Alfa-2a: Results of Myeloproliferative Neoplasms Research Consortium (MPN-RC) 111 and 112 Trials. Blood, 2020, 136, 19-21.	0.6	0
152	Current treatment of myelofibrosis. Clinical Advances in Hematology and Oncology, 2005, 3, 269-70.	0.3	0